From risk stratification to precision surveillance: Interpreting early-warning models after laparoscopic resection for hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with postoperative recurrence representing a major barrier to long-term survival. Advances in minimally invasive surgery, including laparoscopic liver resection, have improved patient outcomes, although early recurrence remains a potential risk. Recent developments in predictive modeling, including least absolute shrinkage and selection operator-based models, have allowed for the incorporation of inflammation, tumor, and hepatic functional reserve factors in personalized risk models. This opinion review aims to evaluate recent developments in early warning models for one-year adverse outcomes in HCC patients undergoing laparoscopic resection. It highlights the biological rationale for tumor-related factors, including alpha-fetoprotein, white blood cell count, tumor invasion, and albumin-bilirubin grade, in early warning models for HCC recurrence. It further discusses potential challenges in validating early warning models, including potential limitations of retrospective model development. It also highlights potential future directions in incorporating artificial intelligence in real-time clinical decision support systems.

Key Words: Hepatocellular carcinoma; Laparoscopic liver resection; Risk prediction; Precision surveillance; Postoperative recurrence

Core Tip: This opinion review discusses the clinical implications of a recently published early-warning model predicting one-year adverse outcomes after laparoscopic resection for hepatocellular carcinoma. The model integrates inflammatory markers, tumor burden, and hepatic reserve to support individualized postoperative surveillance and precision management.

INTRODUCTION

Recent advances in predictive modeling have enabled the development of early-warning systems for estimating one-year adverse outcomes following laparoscopic resection for hepatocellular carcinoma (HCC)[1]. Despite improvements in surgical techniques and perioperative management, early recurrence and poor outcomes are still key predictors of survival in patients who undergo laparoscopic resection for HCC. Primary liver cancer cases are dominated by HCC, which constitutes 75% to 85% of the total cases, and it often presents in the context of underlying chronic liver disease, including cirrhosis resulting from viral hepatitis or metabolic dysfunction-associated steatotic liver disease[2,3]. However, even after curative-intent resection, recurrence has a high likelihood of reaching as high as 50% to 70% in five years, with early recurrence (< 2 years) indicating aggressive tumor behavior and the presence of micro-metastases[4-6]. Current surveillance practices are similar in nature and do not take into consideration the heterogeneity in tumor behavior and underlying liver function.

Currently, the development of predictive models that include a combination of clinical, biochemical, and pathological variables to stratify the recurrence risk has garnered much attention. Such approaches would be in line with the concept of precision medicine in the context of cancer recurrence surveillance and management[7,8].

Conventionally used methods for follow-up after surgery remain largely standardized, often without accounting for the biological heterogeneity of HCC. The referenced study addresses this gap by introducing an early warning system that can predict adverse outcomes in a one-year follow-up based on readily available variables. One of the major advantages of the current study is that it combines inflammatory factors, cancer factors, and measurements of liver function into a single model.

Factors like white blood cell count, alpha-fetoprotein, tumor size, vascular invasion, and the presence of cirrhosis provide information on both the malignant potential and the susceptibility of the patient. Notably, the inclusion of albumin-bilirubin grading helps in the evaluation of the hepatic reserve, often underestimated during the prediction of recurrence.

Multiple clinical, tumor-related, inflammatory, and imaging factors contribute to recurrence risk (Table 1), and their integration into predictive frameworks is illustrated in Figure 1. The global burden of HCC continues to rise, particularly in regions with high prevalence of hepatitis B and C, with emerging contributions from metabolic dysfunction-associated steatotic liver disease[9-12]. Despite advances in surgical techniques, recurrence remains the dominant determinant of long-term survival, emphasizing the need for improved predictive strategies[13-16].

Figure 1 Conceptual framework for risk-stratified surveillance in hepatocellular carcinoma after laparoscopic resection. The figure illustrates the integration of clinical, tumor-related, inflammatory, and hepatic functional variables into predictive models such as least absolute shrinkage and selection operator or machine learning algorithms. Based on model outputs, patients are stratified into low-risk and high-risk groups, enabling tailored follow-up strategies and early intervention to improve clinical outcomes. LASSO: Least absolute shrinkage and selection operator; FU: Follow-up; ML: Machine learning.

Table 1 Key determinants and clinical implications of early recurrence in hepatocellular carcinoma after laparoscopic resection.

Domain	Variables	Pathophysiological basis	Clinical implication
Tumor biology	Tumor size, vascular invasion, AFP	Reflects tumor aggressiveness and metastatic potential	Higher recurrence risk and need for closer surveillance
Inflammation	WBC count, NLR, cytokines	Indicates systemic inflammatory response and tumor-promoting environment	Identifies high-risk patients
Liver function	Albumin-bilirubin grade, cirrhosis	Reflects hepatic reserve	Guides treatment planning
Imaging features	Tumor heterogeneity, vascular patterns	Surrogate markers of tumor biology	Improves prediction
Clinical factors	Age, comorbidities	Affects recovery and disease progression	Influences surveillance strategy
Emerging factors	AI models, radiomics	Multi-dimensional predictive integration	Enables precision medicine

AFP: Alpha-fetoprotein; WBC: White blood cell; NLR: Neutrophil to lymphocyte ratio; AI: Artificial intelligence.

PREDICTIVE MODELS FOR POSTOPERATIVE RISK STRATIFICATION

Predictive modeling has been identified as a major tool in the risk stratification of patients with HCC in the postoperative period. Routine prognostic systems, including the Barcelona Clinic Liver Cancer staging system and the tumor node metastasis staging system, provide overall risk assessment but lack the predictive accuracy for the individual patient[9,10]. Machine learning and regression analysis, including the least absolute shrinkage and selection operator regression, provide a more reliable selection of variables and stability in the model, allowing for the assessment of multi-dimensional variables in the patient[17,18].

Tumor size, microvascular invasion, levels of alpha-fetoprotein, and inflammatory markers such as the neutrophil-lymphocyte ratio have been identified as major risk factors in the early recurrence of the tumor[19-22]. However, a number of aspects do require mention. As with all retrospective models, generalizability becomes a concern. The skill sets associated with surgery and patient selection would vary from institution to institution and could impact the accuracy of the model. Static variables may not reflect the dynamic postoperative state that requires a more comprehensive set of variables that could include biomarkers or imaging variables[13-16,23-26].

On balance, this work is an important step towards more tailored post-operative management following HCC. Future research directions would then include external validation, implementing these algorithms directly within clinical practice, as well as assessing whether risk-adjusted surveillance recovers improved outcomes. Transitioning towards more intervention-oriented research would help to maximize potential survival gains from early warning algorithms.

Several studies have demonstrated that composite scoring systems outperform single-parameter predictors, particularly when integrating tumor biology and systemic inflammatory response[23-26]. Furthermore, the incorporation of imaging biomarkers, including radiological tumor heterogeneity and vascular patterns, has improved predictive accuracy[27-30].

CLINICAL IMPLICATIONS FOR PRECISION SURVEILLANCE

Risk prediction models have the potential to transform postoperative surveillance strategies. Instead of uniform follow-up schedules, clinicians may adopt risk-adapted monitoring protocols in which patients identified as high risk receive more intensive imaging and biomarker surveillance. Such approaches align with the broader movement toward precision oncology.

By integrating patient-specific data, clinicians can better anticipate recurrence patterns and intervene earlier. Furthermore, predictive models may support multidisciplinary decision-making by providing quantitative estimates of risk that complement clinical judgment. The integration of predictive algorithms into electronic health systems may further enhance real-time clinical decision support. Automated risk calculation could assist clinicians in stratifying patients immediately after surgery and adjusting follow-up strategies accordingly.

BIOLOGICAL BASIS OF EARLY RECURRENCE

The mechanism behind early recurrence after HCC resection is multifactorial, including the presence of micro-remnants and tumor microenvironment. Angiogenesis, immune escape, and chronic inflammation are the key factors in the progression and recurrence of tumors[17-20]. Increased inflammatory indices, including interleukin-6 and C-reaction protein, have also been shown to affect prognosis by promoting systemic inflammatory responses[31,32]. Liver reserve capacity is another factor affecting the prognosis. Albumin-bilirubin grade has been shown to be a strong predictive factor in liver reserve capacity compared to the Child-Pugh system in the prognosis of liver cancer patients[33,34].

LIMITATIONS AND FUTURE DIRECTIONS

Despite their promise, predictive models derived from retrospective datasets must be interpreted cautiously. Institutional differences in surgical expertise, patient selection, and perioperative management may limit generalizability across centers. Additionally, static variables collected at the time of surgery may not adequately capture the dynamic postoperative state.

Future models could incorporate longitudinal biomarkers, imaging findings, and molecular signatures to improve predictive accuracy. External validation in independent cohorts and prospective clinical studies will be essential before widespread clinical implementation. Ultimately, research should also determine whether risk-adapted surveillance strategies based on predictive modeling translate into measurable improvements in survival. Most currently available models are derived from retrospective cohorts and lack external validation across diverse populations[35-38]. Additionally, variations in imaging protocols, surgical techniques, and follow-up strategies limit generalizability[39-42].

ARTIFICIAL INTELLIGENCE AND FUTURE DIRECTIONS

Artificial intelligence-based predictive models are increasingly being explored in HCC management. Deep learning algorithms integrating imaging, genomic, and clinical data have demonstrated improved predictive performance compared to traditional statistical models[43-46]. Future models should be designed to assess patient risk dynamically, incorporating longitudinal information and real-time clinical data[47,48]. Integration of radiomics, genomics, and clinical parameters represents a promising direction toward precision oncology[49,50].

EMERGING SYSTEMIC THERAPIES AND THEIR IMPLICATIONS FOR POSTOPERATIVE RISK STRATIFICATION

Recent advances in systemic therapy for HCC have significantly altered the treatment landscape, with implications for postoperative management and recurrence risk assessment. Targeted therapies such as sorafenib have demonstrated survival benefits in advanced disease, while newer agents including immune checkpoint inhibitors and combination regimens have further improved outcomes in selected patients[51-54].

The introduction of immunotherapy-based combinations, particularly atezolizumab plus bevacizumab, has highlighted the importance of tumor biology and microenvironment in determining therapeutic response[55]. These developments suggest that postoperative risk stratification models may benefit from incorporating systemic therapy responsiveness as an additional variable.

Furthermore, the expanding role of adjuvant and neoadjuvant therapies underscores the need for predictive models that extend beyond static clinicopathological variables to include treatment-related factors[56-60]. Integration of these parameters may enable a more comprehensive and dynamic approach to risk assessment, ultimately improving individualized patient management.

CONCLUSION

Predictive modeling represents an emerging tool for optimizing postoperative management in patients undergoing laparoscopic resection for HCC. By integrating inflammatory, oncologic, and hepatic functional parameters, early-warning systems may enable more individualized surveillance strategies. While promising, broader validation and integration into clinical workflows will be necessary to fully realize the potential of predictive analytics in HCC care.